Clinical Vignette
A patient with severe hypercalcemia in multiple organ dysfunction syndrome: Role of elevated circulating 1α,25(OH)2vitamin D levels
Article first published online: 14 JAN 2010
DOI: 10.1002/jbmr.18
Copyright © 2010 American Society for Bone and Mineral Research
Additional Information
How to Cite
Kazama, J. J., Yamamoto, T., Oya, H., Yamamoto, S., Sato, Y., Sakurada, J., Honda, T., Endoh, H. and Narita, I. (2010), A patient with severe hypercalcemia in multiple organ dysfunction syndrome: Role of elevated circulating 1α,25(OH)2vitamin D levels. J Bone Miner Res, 25: 1455–1459. doi: 10.1002/jbmr.18
Publication History
- Issue published online: 27 MAY 2010
- Article first published online: 14 JAN 2010
- Accepted manuscript online: 14 JAN 2010 12:00AM EST
- Manuscript Accepted: 29 DEC 2009
- Manuscript Revised: 16 NOV 2009
- Manuscript Received: 20 AUG 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- sepsis;
- systemic inflammatory response syndrome;
- multiple organ dysfunction syndrome;
- hypercalcemia;
- 1α,25- dihydroxyvitamin D
Abstract
A 54-year-old man was transferred to our ICU because of systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS). He died after 38 days of intensive care. During treatment, his serum calcium (Ca) levels continued to increase and reached 3.95 mmol/L, while the ionized Ca levels reached 2.30 mmol/L before his death. He presented with severe kidney injury, pancreatitis, and hemorrhagic gastric erosion that worsened his prognosis; these were possibly associated with the hypercalcemia. His circulating 1α,25-dihydroxyvitamin D [1,25(OH)2D] level was elevated (75.7 to 204 pg/mL), whereas the levels of 25-hydroxyvitamin D, parathyroid hormone, and parathyroid hormone–related peptide were not. Liver histology revealed immunoreactivity for 25-hydroxyvitamin D 1α-hydroxylase (CYP27B1) in some of the hepatocytes, in which the localization pattern was similar to that of lysozyme-positive hepatocytes. Our ICU has previously encountered 22 similar MODS patients who presented with hypercalcemia over the last 8 years. SIRS with severe kidney and liver injuries are common clinical findings in hypercalcemic patients with MODS. Of the 23 hypercalcemic MODS patients, including the present patient, 17 had circulating 1,25(OH)2D levels exceeding 70 pg/mL despite severe kidney injury. Extrarenal activation of CYP27B1 seems to play a role in the development of hypercalcemia in this disease condition. Clinicians need to be aware that severe hypercalcemia may occur in MODS patients. © 2010 American Society for Bone and Mineral Research

1523-4681/asset/olbannerleft.gif?v=1&s=d7e4c0e37904a489128d3a4e58ba94214db307a9)
1523-4681/asset/olbannerright.gif?v=1&s=854ee0e4d351ead9faaca8bfab3e50b1c7c9d03d)
